QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
250
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
QTX3034
COMBINATION_PRODUCT:
Cetuximab
Sponsor
Quanta Therapeutics